What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?
Petrini P. Petrini P.
. Delahoy MJ, et al. MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1255-1260. doi: 10.15585/mmwr.mm7036e2. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34499627
. No abstract available.